2Backer GJ, Hewitson TD. The role of tubulointerstital injury in chronic renal failure. Curr Opin Nephrol Hypertens, 2000, 9(2) : 133 - 138.
3Wada T, Furuichi K, Sakai N, et al. Gene therapy via blockade of monocyte chemoattractant protein - 1 for renal fibrosis. J Am Soc Nephrol, 2004,15 (4) :940 - 948.
4Viedt C, Dechend R, Fei J, et al. MCP - 1 induces inflammatory activation of human tubular epithelial cells: involovement of the transcription factors, nuclear factor - B and activating protein - 1.J Am Soc Nephrol, 2002, 13(6) : 1534 - 1547.
5Rhyu DY, Yang Y, Ha H, et al. Role of reactive oxygen species in TGF - betal - induced mitogen - activated protein kinase activation and epithelial - mesenchymal transition in renal tubular epithelial cells. J Am Soc Nephrol. 2005 , 16(3) :667 -675.
6Roberts AB, Tian F, Byfield SD, et al. Smad3 is key to TGF - beta - mediated epithelial - to - mesenchymal transition, fibrosis, tumor suppression and metastasis. Cytokine Growth Factor Rev. 2006 , 17 (1 -2) :19 -27.
7Liu Y. Renal fibrosis: new insights into the pathogenesis and therapeutics. Kidney Int. 2006,69(2) :213 -217.
8Forino M, Torregrossa R, Ceol M, et al. TGFbeta1 induces epithelial -mesenchymal transition, but not myofibroblast /ransdifferentiation of human kidney tubular epithelial cells in primary culture. Int J Exp Pathol. 2006 , 87(3) :197 -208.
9Ziyadeh FN,Wolf G. Pathogenesis of the podocytopathy and proteinuria in diabetic glomerulopathy. Curr Diabetes ,2008,4( 1 ) :39 -45.
10Wada T, Yokoyama H. Molecular biology in regulation of kidney functions : MCP - 1/CCR2. Nippon Rinsho, 2006, 64 ( suppl 2 ) : 288 - 292.
3Collins AJ, Couser WG, Dirks JH, et al. World Kidney Day: an idea whose time has come Kidney Int, 2006, 69(5): 781
4Liu SX, Hou FF, Guo ZJ, et al. Advanced oxidation protein products accelerate atheroselerosis through promoting oxidative stress and inflarmnation. Arterioscler Thromb Vase Biol, 2006,26(5) : 1156
5Li HY, Hou FF, Zhang X, et al. Advanced oxidation protein products accelerate fibrosis in a remnant kidney model. J Am Soc Nephrol, 2007,18(2) : 528
6Hou FF, Ren H, Owen WFJr, et al. Enhanced expression of receptor for advanced glycation end products in chronic kidney disease. J Am Soc Nephrol, 2004, 15(7): 1889
7Li JT, Hou FF, Guo ZJ, et al. Advanced glycation end products upregulate C-reactive protein synthesis by human hepatocytes through stimulation of monocyte IL-6 and IL-113 production. Stand J Immunol, 2007, 66(5) : 555
8Feng JX, Hou FF, Liang M, et al. Restricted intake of dietary advanced glycation end products retards renal progression in the remnant kidney model. Kidney Int, 2007, 71(9): 901
9Uribarri J, Peppa M, Cai W, et al. Restriction of dietary glycotoxins reduces excessive advanced glycation end products in renal failure patients. J Am Soc Nephrol, 2003, 14(3): 728
10Fujihara CK, Velho M, Malheiros DM, et al. An extremely high dose of losartan affords superior renoprotection in the remnant model. Kidney Int, 2005, 67(5): 1913
5Strutz F, Zeisberg M. Renal fibroblasts and myofibroblasts in chronic kidney disease [J]. Am Soc Nephrol, 2006, 17( 11 ) : 2992-2998.
6Liu Y. Renal fibrosis: new insights into the pathogenesisand therapeutics [ J ]. Kidney Int, 2006,69 ( 2 ) : 213-217.
7Eddy A A. Molecular basis of renal fibrosis [J]. Pediatr Nephrol, 2000, 15(3-4) : 290-301.
8Seccia T M, Maniero C, Belloni A S,et al. Role of angiotensin Ⅱ , endothelin-1 and L-type calcium channel in the development of glomerular, tubulointerstitial and perivascular fibrosis [J]. J Hypertens, 2008, 26(10):2022-2029.
9Tan A L, Fordes J M, Cooper M E. AGE, RACE, and Ros in diabetic nephropathy [ J ]. Semin Nephrol , 2007,27 ( 2 ) : 130-143.
10Forine M, Torregrossa R, Ced M, et al. TGF-beta1 induce epithelail mesenchymal transition but not myofibroblast transdifferentiation of human kidney tubular epithelial cell in primary allture [J]. Int J Exp Pathol, 2006,87 (3) : 197-208.
